Benefits and risks of pharmacological agents used for the treatment of menorrhagia

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Menorrhagia affects the lives of many women. The assessment of menstrual flow is highly subjective and gauging the severity of the condition by objective assessment of menstrual blood loss is impractical. In treating menorrhagia, the primary aim should be to improve quality of life. Women are willing to undergo quite invasive treatment in order to achieve this. Drug therapy is the initial treatment of choice and the only option for those who wish to preserve their reproductive function. Despite the availability of a number of drugs, there is a general lack of an evidence-based approach, marked variation in practice and continuing uncertainty regarding the most appropriate therapy. Adverse effects and problems with compliance also undermine the success of medical treatment. This article reviews the available literature to compare the efficacy and tolerability of different medical treatments for menorrhagia.

Tranexamic acid and mefenamic acid are among the most effective first-line drugs used to treat menorrhagia. Despite being used extensively in the past, oral luteal phase norethisterone is probably one of the least effective agents. Women requiring contraception have a choice of the combined oral contraceptive pill, levonorgestrel-releasing intrauterine system (LNG-IUS) or long-acting progestogens. Danazol, gestrinone and gonadotropin-releasing hormone analogues are all effective in terms of reducing menstrual blood loss but adverse effects and costs limit their long-term use. They have a role as second-line drugs for a short period of time in women awaiting surgery.

While current evidence suggests that the LNG-IUS is an effective treatment, further evaluation, including long-term follow up, is awaited. Meanwhile, the quest continues for the ideal form of medical treatment for menorrhagia - one that is effective, affordable and acceptable.

Original languageEnglish
Pages (from-to)75-90
Number of pages15
JournalDrug Safety
Volume27
Issue number2
DOIs
Publication statusPublished - 2004

Keywords

  • MENSTRUAL BLOOD-LOSS
  • LEVONORGESTREL INTRAUTERINE SYSTEM
  • DEPOT-MEDROXYPROGESTERONE ACETATE
  • QUALITY-OF-LIFE
  • RANDOMIZED CONTROLLED-TRIAL
  • DOUBLE-BLIND TRIAL
  • MEFENAMIC-ACID
  • TRANEXAMIC ACID
  • IDIOPATHIC MENORRHAGIA
  • UNEXPLAINED MENORRHAGIA

Cite this

Benefits and risks of pharmacological agents used for the treatment of menorrhagia. / Roy, Somendra; Bhattacharya, Siladitya.

In: Drug Safety, Vol. 27, No. 2, 2004, p. 75-90.

Research output: Contribution to journalArticle

@article{a0cdccfc1bff4933a559854b72e28565,
title = "Benefits and risks of pharmacological agents used for the treatment of menorrhagia",
abstract = "Menorrhagia affects the lives of many women. The assessment of menstrual flow is highly subjective and gauging the severity of the condition by objective assessment of menstrual blood loss is impractical. In treating menorrhagia, the primary aim should be to improve quality of life. Women are willing to undergo quite invasive treatment in order to achieve this. Drug therapy is the initial treatment of choice and the only option for those who wish to preserve their reproductive function. Despite the availability of a number of drugs, there is a general lack of an evidence-based approach, marked variation in practice and continuing uncertainty regarding the most appropriate therapy. Adverse effects and problems with compliance also undermine the success of medical treatment. This article reviews the available literature to compare the efficacy and tolerability of different medical treatments for menorrhagia.Tranexamic acid and mefenamic acid are among the most effective first-line drugs used to treat menorrhagia. Despite being used extensively in the past, oral luteal phase norethisterone is probably one of the least effective agents. Women requiring contraception have a choice of the combined oral contraceptive pill, levonorgestrel-releasing intrauterine system (LNG-IUS) or long-acting progestogens. Danazol, gestrinone and gonadotropin-releasing hormone analogues are all effective in terms of reducing menstrual blood loss but adverse effects and costs limit their long-term use. They have a role as second-line drugs for a short period of time in women awaiting surgery.While current evidence suggests that the LNG-IUS is an effective treatment, further evaluation, including long-term follow up, is awaited. Meanwhile, the quest continues for the ideal form of medical treatment for menorrhagia - one that is effective, affordable and acceptable.",
keywords = "MENSTRUAL BLOOD-LOSS, LEVONORGESTREL INTRAUTERINE SYSTEM, DEPOT-MEDROXYPROGESTERONE ACETATE, QUALITY-OF-LIFE, RANDOMIZED CONTROLLED-TRIAL, DOUBLE-BLIND TRIAL, MEFENAMIC-ACID, TRANEXAMIC ACID, IDIOPATHIC MENORRHAGIA, UNEXPLAINED MENORRHAGIA",
author = "Somendra Roy and Siladitya Bhattacharya",
year = "2004",
doi = "10.2165/00002018-200427020-00001",
language = "English",
volume = "27",
pages = "75--90",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Benefits and risks of pharmacological agents used for the treatment of menorrhagia

AU - Roy, Somendra

AU - Bhattacharya, Siladitya

PY - 2004

Y1 - 2004

N2 - Menorrhagia affects the lives of many women. The assessment of menstrual flow is highly subjective and gauging the severity of the condition by objective assessment of menstrual blood loss is impractical. In treating menorrhagia, the primary aim should be to improve quality of life. Women are willing to undergo quite invasive treatment in order to achieve this. Drug therapy is the initial treatment of choice and the only option for those who wish to preserve their reproductive function. Despite the availability of a number of drugs, there is a general lack of an evidence-based approach, marked variation in practice and continuing uncertainty regarding the most appropriate therapy. Adverse effects and problems with compliance also undermine the success of medical treatment. This article reviews the available literature to compare the efficacy and tolerability of different medical treatments for menorrhagia.Tranexamic acid and mefenamic acid are among the most effective first-line drugs used to treat menorrhagia. Despite being used extensively in the past, oral luteal phase norethisterone is probably one of the least effective agents. Women requiring contraception have a choice of the combined oral contraceptive pill, levonorgestrel-releasing intrauterine system (LNG-IUS) or long-acting progestogens. Danazol, gestrinone and gonadotropin-releasing hormone analogues are all effective in terms of reducing menstrual blood loss but adverse effects and costs limit their long-term use. They have a role as second-line drugs for a short period of time in women awaiting surgery.While current evidence suggests that the LNG-IUS is an effective treatment, further evaluation, including long-term follow up, is awaited. Meanwhile, the quest continues for the ideal form of medical treatment for menorrhagia - one that is effective, affordable and acceptable.

AB - Menorrhagia affects the lives of many women. The assessment of menstrual flow is highly subjective and gauging the severity of the condition by objective assessment of menstrual blood loss is impractical. In treating menorrhagia, the primary aim should be to improve quality of life. Women are willing to undergo quite invasive treatment in order to achieve this. Drug therapy is the initial treatment of choice and the only option for those who wish to preserve their reproductive function. Despite the availability of a number of drugs, there is a general lack of an evidence-based approach, marked variation in practice and continuing uncertainty regarding the most appropriate therapy. Adverse effects and problems with compliance also undermine the success of medical treatment. This article reviews the available literature to compare the efficacy and tolerability of different medical treatments for menorrhagia.Tranexamic acid and mefenamic acid are among the most effective first-line drugs used to treat menorrhagia. Despite being used extensively in the past, oral luteal phase norethisterone is probably one of the least effective agents. Women requiring contraception have a choice of the combined oral contraceptive pill, levonorgestrel-releasing intrauterine system (LNG-IUS) or long-acting progestogens. Danazol, gestrinone and gonadotropin-releasing hormone analogues are all effective in terms of reducing menstrual blood loss but adverse effects and costs limit their long-term use. They have a role as second-line drugs for a short period of time in women awaiting surgery.While current evidence suggests that the LNG-IUS is an effective treatment, further evaluation, including long-term follow up, is awaited. Meanwhile, the quest continues for the ideal form of medical treatment for menorrhagia - one that is effective, affordable and acceptable.

KW - MENSTRUAL BLOOD-LOSS

KW - LEVONORGESTREL INTRAUTERINE SYSTEM

KW - DEPOT-MEDROXYPROGESTERONE ACETATE

KW - QUALITY-OF-LIFE

KW - RANDOMIZED CONTROLLED-TRIAL

KW - DOUBLE-BLIND TRIAL

KW - MEFENAMIC-ACID

KW - TRANEXAMIC ACID

KW - IDIOPATHIC MENORRHAGIA

KW - UNEXPLAINED MENORRHAGIA

U2 - 10.2165/00002018-200427020-00001

DO - 10.2165/00002018-200427020-00001

M3 - Article

VL - 27

SP - 75

EP - 90

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 2

ER -